Cybin Inc.

NYSE:CYBNHealthcare · Biotechnology

Mkt Cap-

Float17.4M

Shares O/S-

Inst Own-

Dilution

Mkt Cap-

Float17.4M

O/S-

Inst Own-

Dilution

NYSE:CYBN

MCap-

Float17.4M

O/S-

Inst Own-

Dilution

Historical Data

Date	Open	High	Low	Close	Volume

Analyst Coverage

ConsensusBuy

Price Target

Not available

Ratings Distribution

BUY

HOLD

SELL

TOTAL4

Insider Trades

Insider	Title	Type	Shares	Value	Date
Halstead Michael	Chief Executive Officer	Purchase	100.0K	$1.35M	Sep 21, 2026
Glavine Paul	Chief Growth Officer	Purchase	100.0K	$1.25M	Sep 8, 2026
So Eric H. L.	Director	Purchase	100.0K	$1.24M	Sep 8, 2026
So Eric H. L.	Director	Purchase	100.0K	$1.21M	Sep 4, 2026
Glavine Paul	Chief Growth Officer	Purchase	100.0K	$1.18M	Sep 3, 2026
So Eric H. L.	Director	Purchase	95.0K	$1.12M	Sep 1, 2026

Shareholders

Institutional

(102)

Insiderⓘ

(7)

5%+ Owners

(5)

Unattributed (incl. retail)ⓘ

Top Shareholders

Name	Shares	%	Source
Venrock Healthcare Capital Partners III, L.P. · may incl. warrants· reaffirmed 13F Aug 2026	5.1M	9.9%	13G
So Eric H. L. · joint filing· may incl. warrants· filed Sep 2026	4.4M	5.8%	13D
Glavine Paul · joint filing· may incl. warrants· filed Sep 2026	4.4M	5.8%	13D
Venrock Adviser, LLC	3.9M	--	13F
Adage Capital Management, L.P. · also on 13F· joint filing· may incl. warrants· filed Sep 2026	3.3M	5.3%	13G
ORBIMED ADVISORS LLC	3.3M	--	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	3.1M	--	13F
MILLENNIUM MANAGEMENT LLC	2.6M	--	13F
Millennium Management LLC · also on 13F· may incl. warrants· filed Mar 2026	2.4M	4.8%	13G
Deep Track Capital, LP · may incl. warrants· filed Feb 2026	2.4M	4.7%	13G

Sources: 13F, Form 4, 13D/13G

Insiders & Institutional Holders

Insiders

Halstead MichaelChief Executive Officer
Glavine PaulChief Growth Officer
So Eric H. L.Director
Cavers GregChief Financial Officer
Lewis-Hall Freda CDirector
Firestone TheresaDirector
Inamdar AmirDirector
Lawson MarkDirector
Hoskins EricDirector

Top institutional holders

About

Cybin Inc. is a biopharmaceutical firm dedicated to pioneering treatments that leverage psychedelic compounds.

Its research and development portfolio encompasses several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine designed to alleviate anxiety conditions; and CYB005, a phenethylamine derivative aimed at combating neuroinflammation. Beyond its drug pipeline, Cybin has also conceived EMBARK, an innovative form of psychotherapy enhanced by psychedelics. The enterprise's primary base of operations is situated in Toronto, Canada.

Key Metrics

Market Cap--

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership--

SectorHealthcare

IndustryBiotechnology

ExchangeNYSE American

Country

IPO DateSep 13, 2019

Shares Outstanding-

Float17.40M

52-Week Range

Volume

Average Daily Volume--

30d Avg

60d Avg

90d Avg

Earnings

Dividend History

No dividend history available

Compliance Status